bioRxiv · 10.1101/2025.11.13.684643
Brain-wide Genome Editing via STEP-RNPs for Treatment of Angelman Syndrome
Abstract
Brain-wide genome-editing remains a major hurdle for the treatment of neurogenetic disorders. Here, we report a non-viral, non-nanoparticle, chemical modification-based method, called Stimuli-Responsive Traceless Engineering Platform (STEP) that achieves highly efficient and brain-wide genome-editing of neurons in mice. Using cholesterol-based STEP as a lead, we show that a single administration of STEP-ribonucleoproteins (RNPs) results in functional genetic rescue with significant improvements across a battery of neurobehavioral domains in the Angelman syndrome (AS) mouse model. No significant off-target events or general toxicity effects are observed. STEP-RNPs are also highly efficient at editing human neurons and cortical brain organoids differentiated from AS patient-derived iPSCs. scRNA-seq analysis confirms functional genetic rescue via reactivation of Ube3a/UBE3A expression in human and mouse STEP-RNP-treated neuronal cells. Genome editing via STEP-RNPs has broad applications and the potential to treat many other neurogenetic disorders.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Lu, X., Xie, Y., Bao, Y., Yu, J., Wang, Z., Fan, J., Sheu, W. C., Long, G., Tu, Z., Tong, J., Manquen, G., Li, Y., Katta, V., Chow, R., Chen, B., Meng, Z., Ma, Y.-h., Qiu, C., Chen, S., Tsai, S., Kumar, B. D., Hendry, C. E., Jiang, Y.-h., Zhou, J.. 2025-11-14. Brain-wide Genome Editing via STEP-RNPs for Treatment of Angelman Syndrome. https://doi.org/10.1101/2025.11.13.684643
Cite the original work for its findings. Save a collection to share your selection of sources.